Breast cancer+1
RecruitingA Study of Trastuzumab Deruxtecan Treatment for Patients with Early-Stage HER2-Positive or HER2-Low Breast Cancer Who Show Signs of Molecular Relapse
A Study of Trastuzumab Deruxtecan Treatment for Patients with Early-Stage HER2-Positive or HER2-Low Breast Cancer Who Show Signs of Molecular Relapse
- Disease:Breast cancerHER2 positive breast cancer
- Substances:Trastuzumab Deruxtecan
Germany- Participants:18–64 years · 65+ years
- Substances:Trastuzumab Deruxtecan
- Sponsor:Universitaetsklinikum Ulm AöR









